What are the key regulatory considerations for Point-of-Care devices?

Key regulatory considerations include robust human factors engineering, comprehensive risk management addressing diverse use environments, rigorous clinical validation in the intended use setting, and adherence to specific labeling requirements to ensure safe and effective use by non-laboratory personnel.

How does CLIA waiver impact Point-of-Care Diagnostics?

CLIA waiver exempts a test system from complex, high-complexity, or moderate-complexity testing requirements, allowing it to be performed by untrained personnel in various non-laboratory settings like physician offices or pharmacies. Obtaining CLIA waiver status, governed by 42 CFR 493.15, significantly expands the market for a point-of-care device by simplifying the operational requirements for users.

What cybersecurity challenges are unique to Point-of-Care Diagnostics?

Unique cybersecurity challenges include securing data transmission in varied network environments, protecting patient privacy in easily accessible devices, and ensuring device integrity against tampering in less controlled settings. Manufacturers must address these in accordance with FDA's

All terms

Market SegmentsStrategic LandscapePOC

Point-of-Care Diagnostics

Diagnostic tests performed near the patient, outside a central lab.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Point-of-care testing includes lateral-flow rapid tests, handheld blood analyzers (i-STAT), portable molecular platforms (Cepheid GeneXpert, BioFire), and at-home tests. Designed for short turnaround and minimal training.

What the regulation says

Point-of-care diagnostics are subject to the same regulatory oversight as laboratory-based diagnostics, including requirements for design controls, risk management, and quality system regulation as outlined in 21 CFR Part 820 for the FDA, or Annex I of the EU MDR for devices marketed in Europe. Specific considerations arise due to the diverse intended users and use environments, which influence performance claims and labeling requirements, as detailed in FDA guidance documents on Point-of-Care devices.

What this means in practice

CLIA-waived status unlocks the largest commercial markets (physician offices, urgent care, retail pharmacy, OTC). Reimbursement via CPT 87xxx codes with site-of-service modifiers.

Examples

A manufacturer designs a handheld immunoassay device for influenza detection, intended for use in urgent care clinics by nurses, requiring human factors validation to ensure accurate operation with minimal training.
A company develops a portable molecular diagnostic system for infectious diseases, seeking CLIA waiver to enable its adoption in retail pharmacies for rapid patient screening.
A startup innovates an at-home blood glucose monitoring system, necessitating extensive usability testing and clear instructional labeling to comply with regulatory expectations for lay user operation.

Common pitfalls

•A common pitfall is underestimating the human factors engineering challenges associated with diverse user populations and uncontrolled use environments.
•Failing to adequately validate performance characteristics, such as accuracy and precision, in the actual point-of-care setting can lead to significant regulatory issues.
•Misinterpreting CLIA waiver requirements or failing to secure the appropriate CLIA status can severely limit market access and legal distribution.
•Inadequate cybersecurity measures for connected point-of-care devices can pose significant risks to patient data and device functionality, leading to non-compliance with FDA pre-market and post-market cybersecurity guidance.
•Not addressing shelf-life stability and environmental tolerances for storage and transport, which are often more varied in point-of-care settings, is a common oversight.

Frequently asked questions

Regulatory bodies like the FDA consider Point-of-Care Diagnostics as devices intended for use outside a conventional laboratory setting, often by individuals with minimal training, to provide rapid diagnostic results. The definition emphasizes accessibility and immediacy of results for patient management.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Market Segments

Clinical Laboratory Improvement Amendments(CLIA)

U.S. federal standards that govern clinical laboratory testing.

Market Segments

In Vitro Diagnostics(IVD)

Tests performed on biological samples outside the body.

More in Market Segments

· Same category

Market Segments

Aesthetic & Energy-Based Devices

Lasers, RF, ultrasound, cryolipolysis, and IPL systems used for medical and cosmetic indications, body contouring, hair removal, skin tightening, vascular lesions.

Market Segments

AI Imaging Software

Software that analyzes medical images to triage, detect, or quantify disease.

Market Segments

Cardiac Rhythm Management(CRM)

Implantable and external devices that monitor and treat cardiac arrhythmias, pacemakers, ICDs, CRT devices, and insertable cardiac monitors.

Market Segments

Cardiovascular Devices

Devices for diagnosing, monitoring, or treating cardiovascular disease.

Primary references

3 sources

Link health: 3 verified· last checked 2026-06-20

AACC·1MedTech Dive·1AdvaMed·1

Inline markers like [1] jump to the matching reference above.

On this term

Category: Market Segments
Acronym: POC
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Diagnostic tests performed near the patient, outside a central lab.

·CLIA-waived status unlocks the largest commercial markets (physician offices, urgent care, retail pharmacy, OTC).
·Reimbursement via CPT 87xxx codes with site-of-service modifiers.
·Designed for short turnaround and minimal training.

Remember this

Watch out: A common pitfall is underestimating the human factors engineering challenges associated with diverse user populations and uncontrolled use environments.

Related terms

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms